

# Hormonal Contraception Osteoporosis

PharmDr. Martin Šimíček

Hospital Pharmacy St. Anne's University Hospital in Brno

# Case study – Hormonal contraception

**Patient:** woman, 35 years, non-smoker, BMI 26, she has three children

- BP 118/75
- **Family history:** no risk factors in the family described
- **Personal history:** depression
- **Medicine history:** ethinyloestradiol 35 mg/norethisterone 1 mg + citalopram 10mg 1 - 0 - 0
- She comes for an advice. She started taking oral contraceptives (COCPs) **six months ago**. Since then, at time of weekly intervals without contraception she always suffered from **severe headaches - migraine without aura**



# 1. Case study – Hormonal contraception

## Tasks:

1. How does the female hormonal contraception work, **which hormones are involved** and how they change during the period?

Synthetic **estrogen** in the pill works to - **NEGATIVE FEEDBACK**

- Stop the pituitary gland (hypohysis) from producing **follicle stimulating hormone (FSH)** and **luteinizing hormone (LH)** in order to **prevent ovulation**
- Support the **uterine lining (endometrium)** to **prevent breakthrough bleeding** mid-cycle.

Synthetic **progestin** works to:

- Stop the pituitary gland from **producing LH** in order to **prevent egg release**
- Make the **uterine lining inhospitable** to a fertilized egg.
- Partially **limit the sperm's ability to fertilize the egg**
- **Thicken the cervical mucus** to hinder sperm movement (although this effect may not be key to preventing pregnancy).

# Case study – Hormonal contraception

## Tasks:

2. **What types** of **oral** hormonal contraception exist and how do they work?

□ **Progestines/combined**

- Monophasic - one hormone dose over a cycle
- Biphasic - two hormone doses over a cycle
- Triphasic - three hormone doses over a cycle

3. Make an **analysis of prescription**, give active substance, ATC classification, describe the mechanism of action of individual preparations, check the dosage and method of use (morning / evening, before / after meals, etc.)



# 1. Combined oral contraception

## Starting a Regimen

- combination pill—contains both estrogen and **progestin—within 5 days after the beginning of your menstrual period** - protected from pregnancy immediately

## Day-to-Day Use

- Combination pills **most often come in a 21-day or 28-day pack (the package comes with seven reminder pills, sometimes called placebos)**, which contain no active ingredients and are only meant to help you stay on track.
- When taking the **21-day form**, you will simply not take pills during the last week of your cycle, during which you will have your period.

## Keeping a Schedule

- It's best to take your pill **at the same time each day to maximize efficacy**. This way, your body will get used to receiving a hormonal boost regularly - along with a morning routine such as brushing your teeth or putting on your makeup.
- If you miss a day, it **increases your chances of becoming pregnant**. With the progestin-only pill, it is essential to take it at the same time each day.
- If you confirm that you are pregnant, **stop taking the pill**.

## 2. Citalopram



- should be administered in a **single oral daily dose of 20 mg**. Depending on the patient's individual response, the dose can be increased up to a **maximum daily dose of 40 mg** (or decreased)?

### Duration of therapy

- An antidepressant effect usually occurs after **2-4 weeks of treatment**
- Treatment is symptomatic and must be prolonged for a reasonable time, **usually 6 months after withdrawal of the symptoms, to avoid relapse**
- There is **no effect of food** on the absorption
- Citalopram has **little or moderate influence on the ability to drive**

### Side effects:

- drowsiness, nausea, insomnia, and diaphoresis, ejaculatory disorder
- suicidal tendencies, agitation, diarrhea, anxiety, confusion, exacerbation of depression, lack of concentration, tremor, vomiting, anorexia, and xerostomia



# Case study – Hormonal contraception

4. Find the **potential interactions** between agents. How can hormonal contraception interact with certain antidepressants? What is the possible mechanism of this interaction?

## IT ethinylestradiol / norethisterone and citalopram:

- **CYP450, 3A4** - **there is not a problem with citalopram** (it is metabolized through both CYP2D6 and CYP3A4, so one isoenzyme blockade does not matter)
- definitely not to recommend sertraline, it has the highest incidence of premenstrual depressive dysphoria (3-8% of women)
- theoretically, there is an **increased risk of bleeding** (ADR of all SSRIs) - due to **platelet reuptake of serotonin**, thrombocytes - less activity
- Another problem is in the patient's migraine. Tramadol (risk of serotonin syndrome) is not considered, for triptans it is possible with SSRI with caution, it is not recommended.

# Case study – Hormonal contraception

5. Is there an association between **the use of contraception and headaches?** What **side effects** are likely to occur in patients receiving hormonal contraception?

- Irregular cycle (wait 3-5 cycles)
- Weight gain
- Tension in the breast
- Headaches
- Changes in mood, libido disorders ????
- Vaginal discomfort (vaginal inserts with progestines)

6. **Is it necessary to replace** the current hormonal contraception with another, more appropriate for this patient, or to continue the current?

7. What **type of contraception** would recommend to take this patient? What options (dosage forms, products) contraception, oral is available?



# Case study – Hormonal contraception

## Contraindications of COCPs

- ❑ history of deep **vein thrombosis or embolism**
- ❑ demonstrated **thrombophilic status**
- ❑ history of **hormonal dependent tumors** (breast cancer, endometrium, ovarian endometrioid carcinoma and uterine sarcoma)
- ❑ **acute and chronic liver disease** with impairment of function (except for Gilbert's disease), untreated or untreated hypertension and primary pulmonary hypertension or multiple family history of thrombosis

## Contraindications relative

- ❑ **migraines with aura**
- ❑ diabetes mellitus with vascular changes
- ❑ severe prolapse of the mitral valve and other heart defects with a high risk of embolism
- ❑ smoking in women over 35 years of age
- ❑ severe dyslipidemia

# Case study – Hormonal contraception

Migraine without aura **progestine-only contraception**

## Progestines:


- **KI absolute** - only pregnancy and breast cancer
- **Relative** – ictus, spheric heart disease, **acute** VTE, liver, depression, osteoporosis risks
- Also suitable for **higher risk of VTE**, hypertension, heart defects, **vascular migraine**, DM, stroke intolerance, smokers older than 35 years and nursing women

Tabulka 5. Preparáty gestagenní kontracepce

Název	Složení	Forma
Cerazette	desogestrel 75 µg	28 tablet
Depo-Provera 150 mg/ml	medroxyprogesteron acetát 150mg v 1 ml	injekce
Mirena	levonorgestrel 52 mg	nitroděložní tělísko

## 2. Case study - Osteoporosis

- **Patient:** Renata, age 42 years old, smokes 10 cigarettes a day, drink 3 cups of coffee a day, sometimes alcohol - wine
- **Laboratory values:** height 161 cm, weight 54 kg, BP 125/70
- **Personal history:** Depo-Provera as a contraceptive used, currently osteoporosis was diagnosed
- **Drug history:** Depo-Provera 1 month



# Case study - Osteoporosis

## Tasks:


1. What is osteoporosis? **What is the prevalence?**

- **7-8%** of the population - "civilization disease"
- World prevalence of **200 million people** (Czech Rep. 200.000/800.000)
- **¾ patients undiagnosed (or poorly treated)!!!**
- The **osteoporotic fracture** is threatened by every 3th woman and every 5th over age 50
- The fracture of the femoral neck represents a **high mortality rate and the highest incidence of invalidation** (by 2050 assumption of an increase of 310/240%)

# Case study - Osteoporosis

2. What are the common **risk factors** for osteoporosis? What risk factors can be found in this patient?

## OSTEOPOROSIS RISK FACTORS



“Access” (leads to) Osteoporosis

# Case study - Osteoporosis

3. **How is osteoporosis treated?** Describe all types of treatment (pharmacological, physiotherapy, alternative treatment, ...). Which group of medicines are used for the treatment of osteoporosis? What are their main advantages / disadvantages?

## Terapie osteoporózy

- Zmírnění bolesti (kalcitonin)
- Výživa
- Cvičení a fyzioterapie
- Suplementace **kalcia a vitamínu D**
- **Medikamentózní léčba**
- Ortézy, bederní pásy
- Operační léčba
- Sociální podpora
- Aktivní spolupráce pacienta!!!



4 hod/den

## Pharmacological treatment

### Inhibition of bone resorption

- Estrogens
- Bisphosphonates
- (Calcitonin)
- SERM - raloxifene
- **Strontium ranelate**
- Calcium
- Denosumab

anti-resorptive therapies-  
bisphosphonates with the amino group in  
the side chain

### Stimulation of bone formation

- Vitamin D
- Anabolika Teriparatid
- **Strontium ranelate**
- Osteogenon
  - organic elements of bone (ossein) and microcrystalline hydroxyapatite) containing calcium and phosphorus
  - In ossein protein and non-protein substances with a positive effect on the formation of bone tissue.

# Case study - Osteoporosis

4. Is Depo-Provera ideal contraceptive for this patient? Would you possibly suggest any changes and why?
5. Which treatment of osteoporosis you would recommend for this patient ? Suggest specific medications, frequency of dosing, patient counselling.
6. What regime and non-pharmacological measures would you recommend to the patient for optimal treatment of osteoporosis? (nutrition, physical activity, ...).

# Hormonal contraception







Which contraceptives are  
**most effective?**

Which can we recommend  
which woman?


# Pearl index – contraceptive effectiveness

(Failure per 100 females **per 1 year**)

□ Unprotected sexual intercourse	80 - 85
□ Spermicides (local contraceptives)	0.1 - 25
□ Condom (prophylactic)	14
□ Combined HAK	0.1 - 0.4
□ Oral gestagens	0.14 - 9.60
□ Depot gestagens	0.00 - 1.0
□ IUD - Cu	0.2 - 0.8
□ IUD – levonorgestrel	0.02 - 0.2

# The effectiveness of contraception

## Effectiveness



Adapted from Trussell, Kowal.<sup>1</sup> \*"Typical" includes those not following directions exactly.

Reference: 1. Trussell J, Kowal D. The essentials of contraception: efficacy, safety, and personal considerations. In: Hatcher RA, Trussell J, Stewart F, et al. Contraceptive Technology. 17th rev ed. New York, NY: Ardent Media; 1998:211-247

# 1. Local contraceptives

---

What is it?

How do they work?

**How** are they used?

**Who** are they suitable for?

# 1. Local contraceptives

## Mechanism of action:

Destruction of sperm membranes



Use: 5 - 10 minutes before sex act, leave 6 hours after contact,  
**do not wash!**

Do not use alkaline **soaps** for intimate hygiene.



(Nonoxinolum - Patentex oval)

Benzalkonium chloride - **Pharmatex vag. glo., vag.crm.**


# Pharmatex vag glo, gel (260,- Kč)

- **Intimate parts of body wash** 2 hours before and 2 hours after contact - **only with warm water** (due to possible chemical reaction of the **detergent** with Pharmatex)
- The most risky is contact with **classic (solid) soap**, but beware of shower gels.... it applies to both partners, after contact only for a partner (unless you want to continue sex later).
- **Pharmatex** has an **antiseptic effect**, so it protects most microorganisms. And if you have a permanent partner, you do not have to worry.



# For which woman are local contraceptives appropriate?

- Young girl
- Breeding mother
- Premenopausal woman
- Woman treated for varicose
- Smoker
- After a thromboembolic event
- A woman with intermittent (not regular) sexual intercourses
- A woman with high liver tests
- In addition, women who forget to take a contraceptive tablet may use it as an occasional way of protecting them.



## 2. Progestin contraceptives

---

What is it?

What is the **mechanism of action**?

How are the **rules of use**?

What **types** do we know?

Which women are suitable for?



## 2. Progestin contraceptives

- It contains **only progestin** (...desogestrel) – p.o. **Cerazette, Azalia**
- MA: **suppress** ovulation in only 70% of cases, **thicken cervical mucus, suppress endometrial proliferation, reduce motility of oviductes**

Suitable for:

- **nursing mothers**
- women suffering from **migraines**
- women who **can not take estrogen**
  - ▣ VTE of a history
  - ▣ Hypertension
  - ▣ Heart diseases
  - ▣ DM
  - ▣ Smokers older than 35 years



# Progestin contraceptives

- They are used **continuously (28tbl)**, not a normal 7-day pause, **exactly at the same time of day**
- Apply the **missed dose** immediately with the use of barrier protection in the next 7 days
- 1. choice in breast-feeding women (6 weeks after birth = **puerperium**)

Tabulka 5. Preparáty gestagenní kontracepce

Název	Složení	Forma
Cerazette	desogestrel 75 µg	28 tablet
Depo-Provera 150 mg/ml	medroxyprogesteron acetát 150mg v 1 ml	injekce
Mirena	levonorgestrel 52 mg	nitroděložní tělísko

# Progestin contraceptives


- It is necessary to **use it regularly** (after a period of more than **3 hours** - possibility of failure)
- For users **weighing more than 70kg**, the risk of failure also increases
- **ADE:** irregular bleeding (cycle) amenorrhea, acne, hirsutism, headaches, ...
- **Interactions** - when using acetylcysteine containing **mucolytics** at **higher doses than recommended** (more than 600mg / day), it can affect the permeability of the cervical mucus and thereby reduce the effect

# Progestin-only pills (POPs)

- Side effects
  - Headache
  - Breast tenderness
  - Acne/Hirsutism
  - Nausea
  - Spotting
- Contraindications
  - Known or suspected pregnancy
  - Genital bleeding of unknown etiology
  - Liver tumors
  - Acute liver disease


# Depot progestins

- Depot medroxyprogesterone acetate
- (i.m. Depo-provera., s.c. Sayana)
- Patients with **low adherence** to treatment
- Injection each 14 weeks (3 moths)
- **Amenorrhea** in **1/3 of patients** in the first 3 months
- Loss of bone mineral - decrease in bone density
- Fertility is restored in 10-18 months




# IUD with levonorgestrel (Mirena)

(intrauterine device)



- The most reliable reversible contraception
- 0.02mg of levonorgestrel **for 5 years**
- For women who have already given birth
- With monogamous partner, they want **long-term contraception**
- **Apply** in the first 7 days of menstrual bleeding
- Risk of inflammation only during the first 20 days after implementation





# 3. Combined contraceptives



Which hormones are used?

# 3. Combined oral contraceptives

- The **most common method** of contraception
- Always **combinations**:
- **ethinyloestradiol** (estradiol valerate,  $17\beta$ -estradiol) + **progestin**
- Currently, medicines containing **progestins of the third generation**
- **Low-dose hormone** preparations
- Usually one-phase and three-phase combinations





### 3. Combined oral contraceptives

---

What are **dosing regimens** of combined contraception?

# Dosing modes:

- **packing regimens beginning with Sundays** - one tablet a day, starting on **the first Sunday after the onset of menstruation**. If the menstruation begins on Sunday, the first tablet is taken on the same day
- **21-day regimens** - one tablet is taken daily for 21 days, starting on the **5th day of the cycle**. After using all 21 tablets, the contraceptive **is not used for 7 days**, and then new packs are being used
- **28 day regimens** - 1 tablet per day is used continuously

## 3. Combined oral contraceptives



What interactions do you know?

# Combined contraceptives - drug interactions

A) Induction of liver enzymes; **ethinylestradiol is a CYP3A4 substrate**  
- barbiturates, phenytoin, carbamazepine, felbamate, rifampicin, topiramate, primidone, ritonavir

B) Disruption of reabsorption in **enterohepatic circulation**  
(ATB broadband)

The first warning about drug interaction can be **bleeding!**

Up to 30% of women taking OCPs exhibit a **deficiency in folic acid** and deficiency persists for up to 6 months after discontinuation.

They can lower vitamin **B6** and **vitamin C** levels.

# Combined contraceptives



What about the **forgotten dose?**

# Forgotten dose - **follow the PIL!**

## **Combined contraception:**

- if you forgot 1 tablet, take **it as soon as you remember** or 2 tablets the next day
- if forget 2, use 2 for the next 2 days
- if you forget **3 or more, stop taking the tablets**
- in all cases, to **insure contraception by alternative methods**

## **Gestagens:**

- if you forgot to take 1 tablet, take it as soon as possible and then another tablet at the time you have chosen
- if two tablets are forgotten, omit them altogether and take up the next dose at the scheduled time
- if 3 tablets are forgotten, discontinue therapy and provide adjuvant contraception for further menstruation.

# Specific preparations



- ❑ **Evra patch** (norelgestromin and ethinylestradiol)
- ❑ Stable plasma concentrations
- ❑ 1 patch **for 7 days** (3 weeks of application)
- ❑ Pure, dry, uncovered skin (not breast)
- ❑ Never stick to irritated skin
- ❑ One anatomical area within 1 cycle
- ❑ Never stick to the same place twice
- ❑ At exchange day - Replace immediately at any time of day





# Specific preparations





- **NuvaRing vaginal insert** (Etonogestrel 11.7 mg, Etinylestradiol 2.7 mg in 1 vaginal ring)
- Keep it in refrigerator
- application **once a month (3 weeks)**
- If the ring is accidentally ejected, it can be rinsed with cold or lukewarm water (not hot) and immediately re-introduced. If it was outside of the vagina for **less than 3 hours**, contraceptive efficacy is not reduced








Step 2: Choose a position that is comfortable for you.



Step 3: Press the opposite sides of NuvaRing® together and gently insert it.



Step 4: NuvaRing® can be positioned anywhere inside the vagina.



# 4. Postcoital contraception



- High doses of gestagen
- **Postinor - 2 tablets** (750g levonorgestrel) - 1 tablet and the other after 12 hours. 593,- CZK
- **Escapelle 1tbl** - (1500g levonorgestrel), can be used within 48 hours, 72 hours ?? but the sooner it is used the better. 493, - CZK
- **High doses of conventional contraceptives** such as **Microgynon tbl.** (ethinylestradiol, levonorgestrel) at 4tbl. and within 12 hours another 4tbl.
- **Bleeding 3 days after administration**, continuation of OCPs is not contraindicated
- Can be used max. once a week, menstrual cycle disruption
- ADR: headache, nausea, pain of abdomen, if vomiting in the first three hours to give another tablet

# Postcoital contraception

- It is necessary to thoroughly **educate the client and carefully** evaluate the data obtained
- From age of 16
- Pick up - in person
- The reason for contraception. Why?
- Exclusion of pregnancy
- **KI:** malabsorption sy, liver dysfunction, history of ectopic pregnancy...




# ulipristal-acetate (Ellaone) 660,-Kč




- **effective up to 120 hours (5 days) from sexual intercourse**
- therefore it is **not recommended under 18 years**
- A significant limitation is also for nursing women - breastfeeding should be interrupted for at least 36 hours
- Not with severe **liver damage**
- adverse affect for the **ability to drive and use machines**
- until the beginning of further menstruation with a reliable barrier method (condom)
- especially **for cases between 72 and 120 hours** after sexual intercourse, when the two previous products can not be used.

# Osteoporosis



# Calcium regulation



# Bone metabolism

- Bone tissue is **metabolically very active (spongiosa)**
- Continuous **bone remodeling**
  - **osteosorption and formation**
- Both the volume and the strength of the bone depend on the balance of both these processes.

Remodeling is provided by bone cells:


- **osteoclasts** (modified macrophages, bone resorption)
- **osteoblasts** (type of fibrocytes, neoplasm of bone tissue)
- **osteocytes** (resulting from the conversion of osteoblasts) that

# Osteoporosis - systemic disease of the skeleton

- **loss of bone mass** while maintaining a normal ratio between mineral and organic bone
- as a result of a **negative balance** of bone mass
- reducing **bone strength**
- **low bone density**
- deterioration of **bone microarchitecture**
- susceptibility to fractures
- loss of organic and inorganic components (both)




One-sided vertebral dislocation, the thoracic vertebra arches. After the 70th year, the likelihood of compression occurring in the vertebrae of **each second woman**



# Fracture of the proximal femur


- 20-30% of patients per year die after fracture
- 30-40% is permanently dependent on the care of others



Štěpán J, Havelka S, Kamberská Z. Epidemiologie der Osteoporose in der Tschechischen Republic. J Mineralstoffwechsel 2002;9(3):7-13.



# OSTEOPOROSIS RISK FACTORS



“Access” (leads to) Osteoporosis

# Diagnostics of osteoporosis

- Anamnesis - risk factors
- Clinical examination
- Laboratory examination
- **Bone densitometry**
- **X-ray examination**
  - **thoracic and lumbar spine** in lateral projection a
  - lumbar spine in the back projection for verification
  - the presence of fractures of the **vertebral bodies**
  - bone loss can not be determined
- Examination by rehabilitation worker



RTG páteře.

# X-ray Absortiomerty (bone densitometry)

- The standard of diagnostics is
- **Dual-Energy X-Ray Absorptiomerty (DXA)**
- Densitometry output - **Bone Mineral Density, BMD**
- the most quantitatively predictable osteoporotic fracture predictor
- Measurement of predilection sites of fractures: **femoral neck, lumbar spine**




# Bone densitometry

- The result is expressed as the **Planar Bone Density (BMD)** in **g/cm<sup>2</sup>** and compared to the healthy population.

## T-score

comparison of **the measured value versus the mean value of young healthy adults** of the same sex (SD) - dg in postmenopausal women



R... L.

Lieu: 90 ans: 24.09.1911  
150 cm 48 kg Blanc Féminin  
Médecin:

Droit COL FEMORAL DENSITE OSSEUSE

Acquisition: 11.03.2002 (4.7c)  
Analyse: 11.03.2002 (4.7c)  
Impression: 11.03.2002 (4.7c)  
ruffil01.f27







Image Non Diagnostique  
0.75s Moyenne DDM 1.2x1.2m 1.68m  
10/23 40004 2/4 35 200 63 145 95  
R24150 - 13.213 300 Neck Angle = 47




Région	BMD g/cm <sup>3</sup>	Adulte-Jeune <sup>1</sup> % T-Score	Age-Egal <sup>2</sup> % Z-Score
TOTAL	0.523	52 -4.0	85 -0.8



68 year old woman



74 year old woman



# Therapy of osteoporosis





# Therapy of osteoporosis

- Pain relief
  - Nutrition
  - **Exercise and physiotherapy**
  - Supplementation of calcium and vit. D
  - **Medication treatment**
  - Orthoses, lumbar belts
  - Surgery
  - Social support
- 
- Active cooperation of the patient !!!



# Prevention of osteoporosis

- ❑ maximum "**peak bone mass**"
- ❑ treatment of chronic childhood illnesses
- ❑ eliminate risk factors and GIT dysfunction
- ❑ a varied diet - calcium, vitamin D
- ❑ active movement, increase physical activity
- ❑ HRT



# Pharmacological treatment

## Inhibition of bone resorption

- Estrogens
- Bisphosphonates
- (Calcitonin)
- SERM - raloxifene
- Strontium ranelate
- Calcium
- Denosumab

anti-resorptive therapies -  
bisphosphonates with the amino group in  
the side chain

## Stimulation of bone formation

- Vitamin D
- Anabolics Teriparatid
- Strontium ranelate
- Osteogenon
  - organic elements of bone (ossein) and microcrystalline hydroxyapatite) containing calcium and phosphorus
  - In ossin protein and non-protein substances with a positive effect on the formation of bone tissue.



# Calcium - Ca<sup>2+</sup>




# Nutrition - general recommendations

- Daily **3 servings of low fat milk** and dairy products (3 dcl of milk, 1 yoghurt, 50g of cheese)
- Vegetables and fruits rich in calcium
- **Vitamin D (fish, liver, cheeses)**
- Enough movement
- 0 smoking, 0 alcohol, ↓ coffee
- Restrict phosphates (Coca-Cola Processed Cheese)
- Reduce oxalates (rhubarb, asparagus, spinach, cocoa)

# Recommended calcium intake:


- All 19-65 .. 1000 mg
- Men under 65 .. 1500 mg
- Pregnant > 19 years .. 1000mg
- Pregnant <19 years .. 1200mg
- Nursing > 19 years .. 1000mg
- Nursing <19 years .. 1200mg
- Women before and after manopause with HRT .. 1000mg
- Women before and after manopause without HRT .. 1500 mg
- Men and women over 65 with osteoporosis .. 1500 mg
- Men and women over 65 without osteoporosis .. 1000 mg




Apps in the evening, or divide during the day

# Calcium preparations

- increasing the supply of calcium to mineralization
- cheap, as monotherapy, however, little effective
- daily intake sufficient in food (1 g)
- frequent constipation
- therapeutically 500 mg daily
- *calcium lactate or gluconate*
- calcium salts have no documented effect on improving osteoporosis, **but**
- Calcium deficiency is worsening, ranging from 70 years in women



# Vitamin D (cholecalciferol, ergocalciferol)



7-dehydrocholesterol  
(provitamin D<sub>3</sub>)

cholecalciferol  
(vitamin D<sub>3</sub>)

ergosterol  
(provitamin D<sub>2</sub>)

ergocalciferol  
(vitamin D<sub>2</sub>)



# Vitamin D - function

- Stimulates osteoblasts - releases calcium from bone cells and mineralizes bone with this calcium
- stimulates calcium absorption in the intestine - increases the production of calcium-binding protein in the intestine, promotes the transfer of calcium from the intestine to the intestinal epithelial cells
- increase in supply of Ca<sup>2+</sup> (mineralization support)
- increases reabsorption of calcium in the kidneys
- Inhibits bone resorption by PTH suppression
- **vitamin D increases calcium and phosphorus absorption in the intestine, the synthesis and production of parathyroid hormone decreases and mineralization of bone increases.**

# Vitamin D


- 800 IU dose
- ~~Infadin gtt~~
- Vigantol gtt
- Vitamin D Slovakofarma cps
- ~~Calciferol inj.~~
- Combined preparations with calcium

## Analogues of vitamin D


- 1 alpha (OH) D3 - alpha-alkacidol (Rocaltrol cps, Alpha D3)
- 19 clone 1.25 (OH) 2 D2 - paricalcitrilol (Zemplar)



# bisfosfonates



Bisphosphonate



Pyrophosphate

Agent	R <sub>1</sub> side chain	R <sub>2</sub> side chain
Etidronate	-OH	-CH <sub>3</sub>
Clodronate	-Cl	-Cl
Tiludronate	-H	-S-  -Cl
Pamidronate	-OH	-CH <sub>2</sub> -CH <sub>2</sub> -NH <sub>2</sub>
Neridronate	-OH	-(CH <sub>2</sub> ) <sub>5</sub> -NH <sub>2</sub>
Olpadronate	-OH	-(CH <sub>2</sub> ) <sub>2</sub> N(CH <sub>3</sub> ) <sub>2</sub>
Alendronate	-OH	-(CH <sub>2</sub> ) <sub>3</sub> -NH <sub>2</sub>
Ibandronate	-OH	-CH <sub>2</sub> -CH <sub>2</sub> N
Risedronate	-OH	
Zoledronate	-OH	

# Bisphosphonates

Generation	Chemical structure	Examples	Anti-sorption potential
First	Short alkyl or halogen in the side chain	Etidronate	1
		Clodronate	10
Second	Terminally amino group	Tiludronate	10
		Pamidronate	100
		<b>Alendronate</b>	100-1000
Third	Cyclic side ring	<b>Risedronate</b>	1000-10,000
		<b>Ibandronate</b>	1000-10,000
		Zoledronate	10,000+

# Bisfosfonates

- They **reduce activity, adhesion and the number of osteoclasts**
  - They induce **apoptosis** of osteoclasts
  - It prevents the **attachment of osteoclasts** to the surface of the bone
  - They reduce bone turnover
  - Treatment with bisphosphonates leads to the **formation of normal lamellar bone**
  - Mineral density rise (BMD) and tissue mineralization
  - **They do not affect the activity of osteoblasts**
- Effect condition: sufficient supply of calcium and vitamin D

# Interaction at absorption level

- Extremely high affinity for binding to divalent cations ( $\text{Ca}^{2+}$ ,  $\text{Fe}^{2+}$ ) with subsequent reduction in resorption

**optimal adsorption 2 hours before meals**

- ↓ Availability at 69% - 1/2 hour before meals
- ↓ Availability at 10% - with food
- ↓ Availability at 34% - 2 hours after a meal
- Irritation of the esophagus and the stomach in daily dosing does not apply when used at longer intervals
- **No other clinically relevant interactions**

**In the morning, fasting, drink with plenty of clean water and for 30-60 minutes to eat and not to lie**

# Bisphosphonates – dispensation minimum

- standing up, drinking pure water (at least 3 dcl), **30 minutes before a meal**
- Do not crawl, do not chew
- First 30 minutes after a tablet of breakfast until it can lie down again - GER !!!
- **IT:** When taking corticosteroids, absorption of Ca and P from the gut decreases serum Ca levels (possibly hypocalcaemia). The solution is the Ca and D vit.
- Beware of NSAIDs (increase GIT stimulation)

# Bisphosphonates

## Side effects:

- GIT symptoms - dyspepsia, diarrhea, ... (p.o.)
- musculoskeletal pain, temperature (parenteral)
- bone remodeling disorder - low-energy fracture of long bones
- Osteonecrosis jaws ???

**MEDICAL VACANCES FOR 5 YEARS** (treatment effect lasts for 1 year)

## Indication:

- Osteoporotic fractures
- All forms of osteoporosis including OP induced corticosteroids
- Paget's disease
- Hypercalcaemia associated with bone metastases or multiple myeloma





# calcitonin

Miacalcic spr 200IU, Tonocalcin 200IU spr




# SERM -~~raloxifene~~

- selective estrogen receptor modulators & quot;
- Reduces bone turnover to premenopausal level.
- Increases BMD after 2 years by 2-2.5%
- Higher **risk of phlebotrombosis**
- Hot flashes. Cramps in the calves.
- Gynecological bleeding
- It reduces the risk of ICHS and ca mammae.
- It lowers LDL cholesterol but does not increase HDL cholesterol
- the first-line drug in high risk first fracture patients?



# Stroncium ranelate


PROTELOS 2 g granular powder for oral suspension (28x2g)



# Stroncium ranelate

- Trace element, fraction in nature 0.01%
- ranelic acid salt, two stable strontium atoms
- Partially incorporated into hydroxyapatite structure - increases the regularity of crystals and bone strength
- Ranel salt ↑ was available (25%) and improved tolerance
- **increases the replication of osteoblast precursors**, collagen synthesis, and reduces osteoclast differentiation - leads to increased bone formation and decreased bone resorption.
- binding to calcium receptors regulating the secretion of parathormone
- **Increase in new and inhibition of bone resorption 1st. Dual effect medicine !!!**

# Stroncium ranelate



- p.o. availability 25%

**ADE:** rare

- nausea and diarrhea (treatment discontinuation in 2.2% of patients (1.3% placebo))
- headache, dermatitis, or skin eczema, and elevated liver transaminases


**Interaction:**

- The bioavailability of strontium ranelate reduces the adsorption antacid, calcium
- complexes with tetracyclines and quinolones
- taking antacids at least two hours after strontium, concomitant use is acceptable.
- **Served 2 g strontium ranelate - 1 times a day, preferably at bedtime at least 2 hours after dinner**



# teriparatide


- prevention of progression of postmenopausal or glucocorticoid osteoporosis in case of antiresorptive treatment failure - (expensive, only selected osteocenter, max. 2 years)
- The recombinantly obtained **synthetic parathyroid hormone** amino-terminal 1-34 fragment
- Maximum effect: in 12 months
- Intermittent administration, **18 months**
- Injection (s.c. 20µg) abdomen



Obr. 1 Teriparatid [rhPTH(1-34)] – sekvence aminokyselin.


# Analogue of PTH - teriparatide

- stimulation of osteoblasts → **increase in bone formation**
- suppression of bone resorption effect (against PTH-84 AMK)
- Stimulates bone neoplasm
- It increases the formation of OB
- It reduces apoptosis of OB
- Stimulates bone remodeling
- Improves the number and strength of the trabecula
- Improves the strength of the cortical bone and its geometry
- Effect on VEGF - Vascularization
- ↓ risk of fracture by 65-90%






# denosumab (Prolia)



# denosumab (Prolia)



- Patients prefer subcutaneous injection once every 6 months, instead of once a month (77%)
- Freedom Study (10,000 women)
- Patients with renal impairment do not need to adjust the dose
- Elderly patients do not need to adjust the dose.
- Good tolerance, low IT potential
- Studies have shown a reduction in fracture incidence compared to alendronate
  
- Postmenopausal women have decreased levels
  - estrogen - increased expression of RANK ligand -
  - higher activity of osteoclasts



# denosumab

- Denosumab - a new anti-resorptive drug that affects the RANK ligand signal pathway and bone biology
- Positive influence on cortical bone
- High affinity for only RANKL of bone cells without neutralizing antibodies
- Denosumab will not accumulate in the skeleton
- Denosumab is not excreted by the kidneys
- Fast reversibility of bone remodeling after discontinuation of treatment
- **Single monoclonal antibody according to the prescription.**

